Loading
A phase 3 trial testing QL2107 in non-small-cell lung cancer, now recruiting.
A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC is a phase 3 interventional study registered as NCT06754644, led by Qilu Pharmaceutical, and recruiting on the registry. Official title: A Randomised, Double-blind, Multicenter Phase III Clinical Study to Compare the Efficacy and Safety of QL2107 Versus Keytruda® in Combination With Chemotherapy in the Treatment of Metastatic Non-squamous Non-small-cell Lung Cancer. Planned enrolment is 808 participants (estimated). The study started in 2025-01-15 and primary completion is expected in 2026-12. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares QL2107, Qilu Pharmaceutical.
Shares QL2107, Qilu Pharmaceutical.
Shares QL2107, Qilu Pharmaceutical.
Shares QL2107, Qilu Pharmaceutical, Non-small-cell lung cancer.
Shares QL2107, Qilu Pharmaceutical.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/